Apixaban versus Warfarin in Patients with Atrial Fibrillation
2011 · New England Journal of Medicine · 8,769 citations
https://doi.org/10.1056/nejmoa1107039
D
Dan Atar
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
683
Papers
92.3K
Citations
85
h-index
320
i10-index
Dan Atar is an academic researcher from Oslo University Hospital. The author has contributed to research in topics: Atrial Fibrillation Management and Outcomes & Cardiac Imaging and Diagnostics & Acute Myocardial Infarction Research. The author has an h-index of 85, co-authored 581 publications.
ORCID: 0000-0003-1513-8793Papers by this author
works2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
2016 · European Heart Journal · 6,411 citations
https://doi.org/10.1093/eurheartj/ehw210
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
2012 · European Heart Journal · 2,889 citations
https://doi.org/10.1093/eurheartj/ehs253
2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery
2022 · European Heart Journal · 972 citations
https://doi.org/10.1093/eurheartj/ehac270
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
2016 · Kardiologia Polska · 390 citations
https://doi.org/10.5603/kp.2016.0172
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation
2023 · New England Journal of Medicine · 386 citations
https://doi.org/10.1056/nejmoa2310234
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat